What is the next step in managing a patient with a persistent dry cough and normal investigations?

Management of Persistent Dry Cough with Normal Investigations

For a patient with persistent dry cough and normal investigations, you should first determine the duration: if 3-8 weeks (subacute), treat empirically for postinfectious cough, upper airway cough syndrome (UACS), or asthma; if ≥8 weeks (chronic), pursue sequential therapeutic trials for UACS, asthma, and gastroesophageal reflux disease (GERD) before considering this unexplained chronic cough requiring neuromodulator therapy or speech pathology. 1, 2

Algorithmic Approach Based on Duration

Step 1: Classify the Cough Duration

• Subacute cough: 3-8 weeks duration 1
• Chronic cough: ≥8 weeks duration 1

Step 2: Rule Out Red Flags Immediately

Before proceeding with empiric therapy, assess for:

• Hemoptysis
• Other life-threatening symptoms
• Environmental/occupational exposures 1

If any red flags present, pursue urgent diagnostic workup rather than empiric treatment.

Step 3A: For Subacute Cough (3-8 weeks)

The most common causes are postinfectious cough (48.4%), UACS/postnasal drip syndrome (33.2%), and asthma (15.8%) 1.

Empiric treatment approach:

• Trial therapy for postinfectious cough (typically self-limited but may benefit from cough suppressants)
• If rhinorrhea/postnasal drip symptoms: treat for UACS with antihistamine/decongestant combinations
• If wheezing/dyspnea: trial inhaled bronchodilators for asthma
• Follow up in 4-6 weeks to reassess 1

Step 3B: For Chronic Cough (≥8 weeks)

Sequential therapeutic trials are the cornerstone of management 1, 3:

1. First-line empiric trials (4-6 weeks each):

   • UACS: First-generation antihistamine/decongestant for rhinosinus conditions
   • Asthma: Inhaled corticosteroids and bronchodilators (if spirometry suggests or clinical suspicion high)
   • GERD: Lifestyle modifications + proton pump inhibitor therapy (though note: acid suppression alone is no longer recommended as monotherapy) 1

2. Assess treatment adherence and optimization before declaring failure 2

3. Use validated cough severity/quality of life tools to objectively track response 1, 2

Step 4: When Empiric Trials Fail - Unexplained Chronic Cough

If investigations remain normal AND therapeutic trials for the three most common causes fail, this becomes unexplained chronic cough (UCC), representing cough hypersensitivity syndrome 2.

Management options for UCC:

Primary recommendations:

• Multimodality speech pathology therapy (Grade 2C recommendation) - addresses behavioral cough patterns and laryngeal hypersensitivity 2, 4

• Gabapentin trial (Grade 2C recommendation):

  • Start 300 mg once daily
  • Escalate daily as tolerated up to maximum 1,800 mg/day in two divided doses
  • Critical caveat: Discuss side effects and risk-benefit profile upfront
  • Reassess risk-benefit at 6 months before continuing 2
  • This is recommended because quality of life impairment can be severe, and gabapentin has shown improvement in randomized trials

What NOT to do in UCC:

• Do NOT prescribe inhaled corticosteroids if tests for bronchial hyperresponsiveness and eosinophilia (sputum eosinophils, exhaled nitric oxide) are negative (Grade 2B) 2

• Do NOT prescribe proton pump inhibitors if workup for acid GERD is negative (Grade 2C) 2

Key Nuances and Pitfalls

Common pitfall #1: Declaring cough "unexplained" prematurely without adequate therapeutic trials. Each empiric trial should be 4-6 weeks with confirmed patient adherence 2, 5.

Common pitfall #2: Ordering extensive investigations upfront. The 2018 CHEST guidelines emphasize that history, physical exam, chest X-ray, and spirometry are sufficient initially, with additional testing only for red flags or failed empiric therapy 1, 3.

Common pitfall #3: Missing medication-induced cough. Always verify the patient is not on ACE inhibitors or sitagliptin 1.

Emerging consideration: Laryngeal hypersensitivity syndrome is increasingly recognized as a mechanism for unexplained chronic cough, particularly in patients where flexible laryngoscopy demonstrates marked sensitivity 4. This supports the rationale for speech pathology therapy.

Alternative for refractory cases: Low-dose morphine is mentioned in recent literature as preferred over gabapentin by some experts, though the CHEST guidelines specifically recommend gabapentin 3. Newer P2X3 receptor antagonists (gefapixant) are now licensed in some regions but were not part of the 2016 CHEST guidelines 6.

Practical Implementation

At initial visit:

• Confirm normal chest X-ray and spirometry
• Assess cough duration precisely
• Screen for ACE inhibitor use, smoking, occupational exposures
• Use validated cough severity score (0-10 scale) 1

At 4-6 week follow-up:

• Reassess with same validated tool
• If improved: continue therapy
• If unchanged: move to next sequential trial or consider UCC diagnosis

For UCC diagnosis:

• Refer to speech pathology for cough suppression techniques
• Consider gabapentin with informed consent about side effects
• Avoid unnecessary inhaled steroids or PPIs if testing negative